Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Expectations By $0.26 EPS

Krystal Biotech (NASDAQ:KRYS) announced its earnings results on Monday. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.79 by $0.26, FiscalAI reports. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The business had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million.

Here are the key takeaways from Krystal Biotech’s conference call:

• VYJUVEK revenue rose 30% year over year to $127.3 million in the third quarter, supported by continued U.S. demand and international launches. The company ended the quarter with more than $1.2 billion in cash and investments.
• International momentum continued, with $32 million in third-quarter revenue, more than 20 German treatment centers initiating patients, and home administration beginning in France. Italy pricing negotiations are complete, with a launch expected in early 2027, while Spain discussions are progressing.
• Krystal authorized a $400 million share repurchase program to be deployed over two years, citing confidence in its outlook and sufficient resources to fund commercial expansion and pipeline development.
• Early KB113 results in Gorlin syndrome showed regression in more than 80% of assessed lesions, including non-injected lesions, with complete histological clearance in one injected lesion per patient. Management said the findings support discussions with the FDA and could enable a pivotal study involving fewer than 100 patients.
• Several clinical milestones have been pushed out: ocular DEB results are now expected after the February 2027 last-patient visit, NK enrollment and readout are expected in 2027, and CF interim data are anticipated in the first half of 2027. Gross margin also declined to 94% from 96% a year earlier, while net income and diluted EPS fell year over year, partly because the prior-year period benefited from non-recurring tax items.

Krystal Biotech Stock Down 11.0%

Shares of NASDAQ KRYS opened at $295.90 on Tuesday. Krystal Biotech has a 12 month low of $184.02 and a 12 month high of $382.54. The company has a market cap of $8.76 billion, a P/E ratio of 37.08 and a beta of 0.50. The business’s 50 day moving average is $336.45 and its two-hundred day moving average is $308.70.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KRYS shares. Zacks Research lowered Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 23rd. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Bank of America increased their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $377.20.

Insider Transactions at Krystal Biotech

In other news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter adjusted earnings of $2.05 per share, above consensus estimates ranging from $1.79 to $1.92. Revenue rose approximately 30% year over year to $127.34 million, also exceeding expectations. Krystal Biotech Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth in sales of Vyjuvek, the company’s commercial gene-therapy product, supported the quarter and is strengthening the investment case by demonstrating continued commercial traction. Krystal Biotech Beats on Vyjuvek Strength
• Positive Sentiment: Krystal authorized a $400 million share-repurchase program over two years. Buybacks can provide near-term support for the stock, reduce shares outstanding and signal management’s confidence in the company’s cash-generation potential. Krystal Outlines $400 Million Share Repurchase
• Neutral Sentiment: Despite the earnings beat, annual earnings declined from the prior-year quarter, while Krystal revised 2026 non-GAAP operating-expense guidance to approximately $155 million-$165 million. Investors are assessing whether Vyjuvek growth can offset rising investment in the pipeline.
• Negative Sentiment: Timelines for parts of Krystal’s clinical portfolio have shifted into 2027, frustrating investors seeking nearer-term catalysts and increasing execution risk. Krystal’s Q3 Profit Declines as Clinical Portfolio Advances
• Negative Sentiment: At a market capitalization of roughly $8.8 billion and a price above some fair-value estimates, the stock remains demanding. Analysts also flagged risks that funding a large buyback could compete with research spending and other strategic uses of cash. Krystal Biotech Stock Stays Above Fair Value After Buyback Plan

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.